

**IN THE CLAIMS**

In claim 1 please delete "5-15 mg mCi <sup>90</sup>Y conjugate" and replace with -- 5-15 mCi <sup>90</sup>Y conjugate --.

Please cancel, without prejudice, claims 19 through 23.

Please add the following claim:

C1  
26. (new) A method of treating disease associated with elevated levels of Tac-positive cells in humans comprising administering to an afflicted human a therapeutic amount of <sup>90</sup>Y-conjugated anti-Tac to eliminate disease-associated Tac-positive cells, said therapeutic amount comprising 5-15 mCi <sup>90</sup>Y-conjugated anti-Tac in a total amount of 2-20 mg anti-Tac, wherein 2 mg total anti-Tac is administered to afflicted humans with sIL-2R levels of less than 2,000 units/ml, 5 mg total anti-Tac is administered to afflicted humans with sIL-2R levels of 2,000 - 10,000 units/ml, 10 mg of total anti-Tac is administered to afflicted humans with sIL-2R levels of 10,000 - 50,000 units/ml, and 20 mg of total anti-Tac is administered to afflicted humans with sIL-2R levels of greater than 50,000 units/ml.

**REMARKS**

Applicant respectfully requests favorable reconsideration in view of the herewith presented amendment and remarks.

Claims 1-18, and 24-26 are pending in the instant patent application. The amendments to the specification and to claim 1 correct inadvertent errors. Support for new